Document:

Exhibit
10.7

 

AGREEMENT
AND AMENDMENT NO. 4

 

This
AGREEMENT AND AMENDMENT NO. 4 (this “Forth Amendment”) is made this 27 day of June, 2016 by and between ORAMED
Ltd., a company incorporated under the laws of the State of Israel, # 513976712 with an address at High-Tech Park 2/4, Givat
Ram, Jerusalem, Israel 93706 (the “Company”), and KNRY, Ltd., a company incorporated under the
laws of the State of Israel, # 513836502 with an address at 2 Elza Street, Jerusalem, Israel 93706 (the “Consultant”).

 

WHEREAS:

 

A.          
The Company and the Consultant are parties to the Agreement dated as of July 1, 2008 (the “Original Agreement”), as
amended on July 17, 2013 (the “First Amendment”), on November 13, 2014 (the “Second Amendment”) and on
July 21, 2015 (the "Third Amendment" and together with the Original Agreement, the First Amendment and the Second Amendment
- the “Employment Agreement”), for services to be provided by Dr. Miriam Kidron Israeli I.D. number 9665993 (“Miriam”);
and

 

B.            The Company and the Consultant wish to amend the Employment Agreement to revise the terms of the Consultant compensation thereunder.

 

NOW,
THEREFORE, in consideration of the premises and the mutual covenants and agreements herein contained, the parties hereto covenant
and agree as follows:

 

		1.	Amendment
                                         to Section 6. Section 6 of the Original Agreement is hereby amended and restated
                                         in its entirety to read as follows:

 

“Compensation.
Effective from June 2016 (inclusive), the Company shall pay to the Consultant in consideration for the performance of the Consulting
Services, a gross monthly amount of 69,960 + VAT (approximately $18,260) (the “Consideration”), subject to
the receipt by the Company of an invoice from the Consultant. Each of the Consultant and Miriam hereby declares that neither of
them has, nor shall have in the future, any claims or demands in respect of amounts paid prior to May 2008.”

 

		2.	Ratification.
                                         As amended hereby, the Employment Agreement is ratified and confirmed and all other terms
                                         and conditions remain in full force and effect.

 

[Signature
page follows.]

 

     

     

    

 

IN
WITNESS WHEREOF the parties hereto have executed this Third Amendment effective as of the date and year first above written.

 

	ORAMED
    LTD.	 	KNRY
    LTD.
	 	 	 
	Per:	/s/
    Yifat Zommer	 	/s/
    Nadav Kidron, /s/ Miriam Kidron
	Name:	Yifat
    Zommer	 	Name:  Nadav
    Kidron, Miriam Kidron
	Title:	Chief
    Financial Officer and SecretaryExhibit
10.22

 

 

February
5, 2013

 

David
M. Slager

Regals
Capital LP

152
West 57th Street

9th Floor

New
York, NY 10019

 

Dear
David:

 

This
letter is to confirm certain undertakings that Oramed Pharmaceuticals Inc. (the "Company") has made in connection
with your recent investment in the Company. The Company for ten years from October 26, 2012 on will not:

 

		1.	Grant
                                         stock options with an exercise price of less than $6.00 per share, as adjusted for stock
                                         splits and the like; or

 

		2.	Grant
                                         stock options to officers, directors, employees or consultants exercisable into more
                                         than 125,000 shares of common stock of the Company, in the aggregate per calendar year,
                                         without the consent of the top 3 non-founding shareholders (ie top 3 shareholders outside
                                         of Nadav Kidron and Dr. Miriam Kidron and other related parties).

 

Sincerely,

 

/s/
Nadav Kidron

 

Nadav
Kidron, CEO

 

Oramed
Pharmaceuticals, Inc.  |  2 Elza Street, Jerusalem, Israel 93706.  |  www.oramedpharma.com

Phone:
011 972-54-790 9058  |  Fax: 011 972-2-679 2336  |  Email: info@oramedpharma.comExhibit
10.25

 

Second
Amendment to Employment Agreement

 

This
Second Amendment to the Employment Agreement (this “Second Amendment”) is entered into as of this 27 day of June 2016,
by and between Joshua Hexter, an individual residing at Jerusalem, Israel (the “Executive”), and ORAMED
Ltd., a company incorporated under the laws of the State of Israel, with an address at Hi-Tech Park 2/4 Givat Ram, Jerusalem,
Israel 91390 (the “Company”).

 

WHEREAS,
the Company and the Executive entered into an Employment Agreement, dated as of April 15, 2013 (the “Original Agreement”),
which was amended on July 21, 2015 (the "First Amendment" and together with the Original Agreement - the “Employment
Agreement”); and

 

WHEREAS,
Company and the Executive desire to amend some of terms and conditions of the Employment Agreement.

 

NOW,
THEREFORE, the Company and the Executive agree as follows:

 

1.            In Section 2.1(a) - Salary of the Original Agreement, the following paragraph is hereby added:

 

As
of June 1st, 2015, the Executive shall be entitled to a gross monthly salary of NIS 44,891 (the “Salary”).

2.           
Except for the changes and/or additions stated herein, all the other terms of the Original Agreement shall remain valid and bind
the parties without any change. In the case of a contradiction between the provisions of this Amendment and the provisions of
the Original Agreement, the provisions of this Amendment shall prevail. Without limiting the generality of the foregoing, the
term “Agreement” as used in the Employment Agreement shall be deemed to be the Employment Agreement as amended by
this Amendment.

 

IN WITNESS WHEREOF, the parties have executed this Amendment to Employment Agreement as of June 1st,
2016.

 

	 	Oramed
    Ltd.
	 	 
	 	/s/
    Nadav Kidron
	 	Nadav
    Kidron, CEO
	 	 
	 	/s/
    Joshua Hexter
	 	Joshua
    HexterExhibit
10.31

 

**Confidential
portions have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities
and Exchange Commission (the “Commission”)**

 

AGREEMENT

 

This
Agreement (the “Agreement”)
is entered into as of June 3, 2016 (the “Effective Date”) between Hefei
Tianhui Incubator of Technologies Co., Ltd., a corporation organized and existing under the laws of the People’s
Republic of China (“PRC”) and having its principal place of business at No. 199 Fanhua Road, Heifei, Anhui,
China (“HTIT”), and Oramed Ltd., a company organized and
existing under the laws of the State of Israel and having a principal place of business at 2/4
Hi-Tech Park, PO Box 39098, Jerusalem, 91390, Israel (“Oramed”). HTIT and Oramed are sometimes referred to
herein individually as a “Party” and collectively as the “Parties”.

 

RECITALS

 

Whereas,
Oramed and HTIT entered into that certain Amended and Restated Technology License Agreement dated December 21, 2015 (the “License
Agreement”); and

 

Whereas,
pursuant to the License Agreement, Oramed undertook to ensure that HTIT receives certain support and services to enable HTIT to
manufacture ORMD-0801 (the “Product”) and, for this purpose, Oramed undertook, inter alia, to enter
into an agreement with SwissCaps AG (“SwissCaps”) pursuant to which Swisscaps would be involved in the transfer
of certain manufacturing know-how to HTIT; and

 

Whereas,
Oramed and HTIT have agreed that part of the aforementioned transfer of manufacturing know-how concerning, primarily, scale-up/development
work, will now be undertaken by Xertecs GmbH (“Xertecs”), as further described below, while the primary focus
of SwissCaps’ know-how transfer activities will be related to the performance of QbD work; and

 

Whereas,
Xertecs and Oramed have entered into a Services Agreement of even date herewith, a copy of which is attached hereto as Exhibit
A, (the “Xertecs Services Agreement”) pursuant to which XERTECS agreed to collaborate with Oramed to ensure
that the required support and services are provided to HTIT to enable HTIT to manufacture the Product at HTIT’s facilities
(the “Xertecs Services”); and

 

Whereas,
the Parties desire (i) to make certain amendments
to the License Agreement to reflect the involvement of Xertecs in the aforementioned transfer of know-how to HTIT, and (ii) to
set out certain additional matters regarding their respective activities and obligations in connection with the implementation
of the Xertecs Services;

 

Now
Therefore, in consideration of the foregoing
premises and the mutual promises, covenants and conditions contained in this Agreement, the Parties agree as follows:

 

     

     

    

 

Article
1

AMENDMENT TO LICENSE AGREEMENT AND ACKNOWLEDGMENT

 

1.1       Amendment.
For the sake of good order and to reflect the involvement of Xertecs in the transfer of certain manufacturing know-how to HTIT
which Oramed and HTIT initially understood would be performed solely by SwissCaps, as contemplated in the License Agreement, the
Parties hereby replace Exhibit F3 in the License Agreement with the Exhibit C in this Agreement. Except as expressly set out
above, the License Agreement shall remain in full force and effect without amendment.

 

1.2       Acknowledgment.
HTIT hereby acknowledges that it has reviewed the Xertecs Services Agreement and consents to Oramed engaging Xertecs to provide
the Xertecs Services in accordance with the terms thereof. However, both parties agree that it is the sole responsibility of Oramed
to supervise and manage Xertec’s performance of its obligations under the Xertecs Services Agreement. A direct loss caused
to HTIT due to a material breach by Oramed of the Xertecs Services Agreement shall be borne by Oramed.

 

Article
2

ORAMED’s RESPONSIBILITIES

 

2.1       Oramed’s
Responsibilities. In the context of the contemplated transfer of know-how from Xertecs to HTIT, Oramed undertakes to perform
the following activities:

 

(a)       Performance
of analytical lab tech transfer

 

(b)       Drug
packaging tech transfer

 

(c)       Preparation
and delivery of the soft gel QbD (“Swiss Caps QbD Agreement” a copy of which is attached hereto as
Exhibit B)

 

(d)       Establishment
of mini pilot plant for soft gel capsule manufacturing: Oramed will be responsible for setting up a mini-pilot plant for
soft gel capsule manufacturing in accordance with the work-plan. It is hereby clarified and agreed that the budget will be funded
by the Oramed and HTIT in accordance with the allocation set out in line items 50 through 57 of Exhibit C of the License Agreement.
For clarity, the cost of Xertecs in supporting setting up of the mini-pilot plant and final commercial scale plant, and the expenses
of Oramed and its subcontractors incurred during the associated technology transfer and services will be borne by Oramed.

 

2.2       Designated
Personnel. Oramed also undertakes to procure from Xertecs a Memorandum of Understanding outlining the designated personnel

 

2.3       Notice
of Termination. Pursuant to Section 7.3 of the Xertecs Services Agreement, Oramed will provide notice of termination to HTIT
within the applicable notice period. Oramed agrees that any direct loss caused to HTIT by such termination, shall be borne by
Oramed. Oramed has rights of recovery and subrogation after paying compensation for such loss to HTIT. For
clarity, should Oramed and HTIT mutually agree to terminate the Xertecs Services Agreement then no compensation shall be due to
HTIT.

 

    	 	2	 

     

    

 

Article
3

HTIT’s RESPONSIBILITIES

 

3.1       HTIT’s
Responsibilities. In the context of the contemplated transfer of know-how from Xertecs to HTIT, HTIT undertakes to perform
the following activities:

 

(a)       Timely
Performance. In accordance with its Pre-Commercialization and Commercialization obligations under the License Agreement, HTIT
shall perform its obligations to design, establish and qualify adequate pharmaceutical manufacturing facilities to meet applicable
GMP requirements for the manufacture of the Product at its facilities in the PRC all in a timely manner and in accordance with
the agreed timelines and work plan.

 

(b)       Notification
of Delay. Without derogating from the obligation set out in Section 3.1(a), in the event that HTIT becomes aware of a delay
in the schedule for designing, establishing and qualifying adequate pharmaceutical manufacturing facilities to meet applicable
GMP requirements for the installation of appropriate manufacturing and processing equipment for the manufacture of the Product
at its facilities in the PRC, HTIT shall immediately inform Oramed of such delay in writing and shall indicate in such notice
to Oramed (i) the reasons for the delay, (ii) the proposed course of remedial action to be undertaken, and (iii) the anticipated
time needed for completing such work.

 

(c)       Work
Plan under the Xertecs Services Agreement. With respect to those matters, work tasks and activities set out in Annex 2 of
the Xertecs Services Agreement that require HTIT’s involvement, Oramed will consult with HTIT in order to obtain HTIT’s
input. Should HTIT fail to respond in 20 calendar days to Oramed’s request for HTIT’s input, HTIT hereby expressly
agrees that it will accept the decision of Oramed and Xertecs with respect to such matters, work tasks and activities, provided
that such decision (A) is reasonable and made in good faith, and (B) is not reasonably expected to cause unreasonable loss of
HTIT. If HTIT disagrees with the abovementioned decision on the basis of either (A) or (B), HTIT shall immediately (but not later
than 15 calendar days from the date such decision is made) provide a written statement to this effect to Oramed with reasons for
such disagreement. In the event that HTIT does not provide such written statement within such 15 calendar day period, HTIT hereby
waives all claims against Oramed and Xertecs with respect to such decision.

 

3.2       General.
In addition, HTIT shall cooperate in good faith with and provide reasonable assistance and support to Oramed and Xertecs,
including by providing access to HTIT’s facilities, in order to ensure the proper implementation and performance of the
Xertecs Services Agreement.

 

Article
4

INFORMATION EXCHANGE AND INTELLECTUAL PROPERTY

 

4.1       Steering
Committee. HTIT acknowledges that pursuant to the Xertecs Services Agreement, Oramed and Xertecs agreed to establish a steering
committee (the “Steering Committee”) to oversee the implementation of the Project (as such term is defined
in the Xertecs Services Agreement), engage in regular Project overview and discuss issues that may arise during such implementation.
As per agreement of Oramed and Xertecs, HTIT shall be entitled to appoint representatives to the Steering Committee who may participate
in all discussions regarding the implementation of the Project to allow for the efficient flow of information among the parties.
The Steering Committee shall be composed of one or two representatives from each of Oramed, HTIT and Xertecs. Decisions of the
Steering Committee shall require unanimous approval by all member of the Committee, (it being clarified that each of Oramed, HTIT
and Xertecs shall have one vote only, regardless of the actual number of representatives they appoint to the Steering Committee).

 

    	 	3	 

     

    

 

4.2       Intellectual
Property. The parties acknowledge that, pursuant to Section 5.1 of the Xertecs Services Agreement, all Results (as such term
is defined in the Xertecs Services Agreement) generated through the provision of the Xertecs Services, and all intellectual property
rights related thereto and subsisting therein, shall become the exclusive property of Oramed. Oramed hereby agrees that such Results
shall be included within the definition of Oramed Know-How, Oramed Inventions, or Joint Inventions (as per the License Agreement),
depending on the way such results are generated.

 

4.3       
Completion of the Oramed Xertecs Service Agreement shall be defined as (1) the transfer of all relevant documents relating to
the capsule manufacturing as listed in Exhibit C (Task ID #18) and G of the Technology License Agreement and (2) the successful
manufacturing and release against predefined specifications of [THE CONFIDENTIAL PORTIONS HAVE BEEN SO OMITTED PURSUANT TO
A REQUEST FOR CONFIDENTIAL TREATMENT AND HAVE BEEN FILED SEPARATELY WITH THE COMMISSION] batches of soft gel capsules in the
final scale (up to [THE CONFIDENTIAL PORTIONS HAVE BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAVE
BEEN FILED SEPARATELY WITH THE COMMISSION] capsules per batch) plant as outlined in the Oramed Xertecs Service Agreement (Task
ID #56 in Exhibit C and Milestone 3 and 4 in Exhibit F3 of the Technology License Agreement).

 

Article
5

Miscellaneous

 

5.1       Termination
and Amendment. This Agreement shall remain in force until completion of the Oramed Xertecs Service Agreement as per Section
4.3. Any material amendments to the Xertecs Services Agreement, including changes to the Designated Personnel, shall require HTIT’s
consent, not to be unreasonably withheld, conditioned or delayed. The termination of this Agreement before the XERTECS Services
Agreement is fully performed does not relieve Oramed of its obligations under the License Agreement to provide for the transfer
of relevant technology for the manufacture of Product capsules.

 

5.2       Disputes.
Disputes, should any arise, between Oramed and HTIT with respect to this Agreement will follow the resolution procedures in the
License Agreement.

 

5.3       Force
Majeure. A Party shall be excused from the performance of its obligations under this Agreement to the extent that such performance
is prevented by force majeure and the non-performing Party promptly provides notice of the prevention to the other Party. Such
excuse shall be continued so long as the condition constituting force majeure continues and the non-performing Party takes reasonable
efforts to remove the condition. For purposes of this Agreement, force majeure shall include conditions beyond the reasonable
control of the non-performing Party, including an act of God or terrorism, involuntary compliance with any regulation, law or
order of any government, war, civil commotion, epidemic, failure or default of public utilities or common carriers, destruction
of production facilities or materials by fire, earthquake, storm or like catastrophe. Notwithstanding the foregoing, a Party shall
not be excused from making payments owed hereunder because of a force majeure affecting such Party. If a force majeure event persists
for more than 90 days, then the Parties will discuss in good faith the modification of the Parties’ obligations under this
Agreement in order to mitigate the delays caused by such force majeure.

 

    	 	4	 

     

    

 

5.4       Notices.
Any notice required or permitted to be given under this Agreement shall be in writing, shall specifically refer to this Agreement,
and shall be addressed to the appropriate Party at the address specified below or such other address as may be specified by such
Party in writing in accordance with this Section, and shall be deemed to have been sufficiently given for all purposes when received,
if in writing and personally delivered, one (1) day following facsimile or email transmission (receipt verified) or two (2) days
following overnight express courier service (signature required), prepaid, to the Party for which such notice is intended, at
the address set forth for such Party below.

 

	 	If to Oramed:	Oramed Ltd.

 2/4
Hi-Tech Village

PO
Box 39098

Jerusalem,
91390, Israel

Attention:
Chief Executive Officer

With
a copy to: Chief Financial Officer

Fax:
+972 (2) 566-0004

Email:yifat@oramed.com

 

	 	If to HTIT:	Hefei Tianhui Incubator of Technologies Co., Ltd.

No.
199 Fanhua Road, Heifei, Anhui, China

Attention: Ms. Coco Lee 

Fax:
+86-551-6384-9089

Email: lixiaopeng@htbt.com.cn

 

5.5       Further
Actions. Both Parties agree to execute, acknowledge and deliver such further instruments, and to do all such other acts, as
may be necessary or appropriate in order to carry out the purposes and intent of this Agreement.

 

5.6       Severability.
If any one or more of the provisions of this Agreement is held to be invalid or unenforceable by any court of competent jurisdiction
from which no appeal can be or is taken, the provision shall be considered severed from this Agreement and shall not serve to
invalidate any remaining provisions hereof. The Parties shall make a good faith effort to replace any invalid or unenforceable
provision with a valid and enforceable one such that the objectives contemplated by the Parties when entering this Agreement may
be realized.

 

5.7       No
Waiver. Any delay in enforcing a Party’s rights under this Agreement or any waiver as to a particular default or other
matter shall not constitute a waiver of such Party’s rights to the future enforcement of its rights under this Agreement,
except with respect to an express written and signed waiver relating to a particular matter for a particular period of time.

 

5.8       English
Language. This Agreement was prepared in the English language, which language shall govern the interpretation of, and any
dispute regarding, the terms of this Agreement. To the extent this Agreement requires a Party to provide to the other Party Information,
correspondence, notice or other documentation, such Party shall provide such Information, correspondence, notice or other documentation
in the English language.

 

5.9       Counterparts.
This Agreement may be executed in one or more counterparts by original or facsimile signature, each of which shall be deemed an
original, but all of which together shall constitute one and the same instrument.

 

5.10     Exhibits.
The following exhibits, attached hereto, form an integral part hereof:

 

Exhibit
A:Xertecs Services Agreement

 

Exhibit
B:Swiss Caps Agreement

 

[Remainder
of page left intentionally blank. Signature page follows immediately.]

 

    	 	5	 

     

    

 

[Signature
page]

 

In
Witness Whereof, the Parties have executed
this Agreement in duplicate originals by their duly authorized officers as of the Execution Date.

 

	Oramed Ltd.	 	Hefei
Tianhui Incubator of Technologies Co., Ltd.
	 	 	 
	By:	/s/ Nadav Kidron	 	By:	/s/ Gao Xiao Ming
	Name:	Nadav Kidron	 	Name:	Gao Xiao Ming
	Title:	Chief Executive Officer	 	Title:	Chairman
	 	 	 	 	 
	Oramed Pharmaceuticals Inc.	 	 	 
	 	 	 	 
	By:	/s/ Nadav Kidron	 	 	 
	Name:	Nadav Kidron	 	 	 
	Title:	Chief Executive Officer	 	 	 

 

    	 	6	 

     

    

 

Exhibit
A

 

Xertecs
Services Agreement 

 

[Exhibit
10.33 to Form 10-K for the fiscal year ended August 31, 2016]

 

    	 	7	 

     

    

 

Exhibit
B

 

Swiss
Caps QbD Agreement

 

[THE
CONFIDENTIAL PORTIONS HAVE BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAVE BEEN FILED SEPARATELY WITH
THE COMMISSION]

 

    	 	8	 

     

    

 

Exhibit
C

 

Amended
Exhibit F3 of the Technology License Agreement

 

Upon
the Satisfaction of Milestones for the Services Agreement

 

	1	USD
    4,000,000	[THE
CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE
COMMISSION]

	2	USD
    2,000,000	[THE
    CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH
    THE COMMISSION]
	3	USD
    2,000,000	[THE
    CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH
    THE COMMISSION]
	4	USD
    8,000,000	[THE
    CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH
    THE COMMISSION]
	5	USD
    1,000,000	[THE
    CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH
    THE COMMISSION]

 

 

 9

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00264-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00264-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00264-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00264-of-00352.parquet"}]]